

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/46770 A2

(51) International Patent Classification⁷: G01N 33/68

(21) International Application Number: PCT/US01/50744

(22) International Filing Date: 22 October 2001 (22.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/242,645 23 October 2000 (23.10.2000) US

(71) Applicant: GENETICS INSTITUTE, LLC [US/US]; 87
Cambridge Park Drive, Cambridge, MA 02140 (US).

(72) Inventors: QIU, Yongchang; 10 Old Colony Lane #7, Ar-
lington, MA 02476 (US). WANG, Jack, H.; 522 Lowell
Street, Lexington, MA 02420 (US). HEWICK, Rodney,
M.; 42 Commonwealth Avenue #4, Boston, MA 02116
(US).

(74) Agents: KODROFF, Cathy, A. et al.; Howson and How-
son, Spring House Corporate Center, P.O. Box 457, Spring
House, PA 19477 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ISOTOPE-CODED IONIZATION-ENHANCING REAGENTS (ICIER) FOR HIGH-THROUGHPUT PROTEIN IDENTIFICATION AND QUANTITATION USING MATRIX-ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY

(57) Abstract: Arginine-containing cysteine-modifying compounds useful for MALDI-MS analysis of proteins are provided. These compounds termed isotope-coded ionization enhancement reagents (ICIER) can provide ionization enhancement in MALDI-MS, relative quantitation, and additional database searching constraints at the same time without any extra sample manipulation. More specifically, ICIER increase the ionization efficiency of cysteine-containing peptides by attachment of a guanidino functional group. ICIER also increase the overall hydrophilicity of these peptides due the hydrophilic nature of ICIER and thus increase the percentage of recovery of these peptides during sample handling and processing such as in-gel digestion or liquid chromatography. Finally, a combination of both light and heavy ICIER provides an accurate way to obtain relative quantitation of proteins by MALDI-MIS and additional database searching constraints (number of cysteine residues in every single peptide peak) to increase the confidence of protein identification by peptide mass mapping.

WO 02/46770 A2

ISOTOPE-CODED IONIZATION-ENHANCING REAGENTS (ICIER) FOR HIGH-THROUGHPUT PROTEIN IDENTIFICATION AND QUANTITATION USING MATRIX-ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY

5

BACKGROUND OF THE INVENTION

The present invention relates to the field of high-throughput protein analysis. More specifically, this invention relates to novel reagents for use in the identification and quantitation of proteins using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in combination with peptide mass fingerprinting or fragment ion-based database searching.

MALDI-MS has become an established tool for the rapid identification of isolated proteins and has been used *inter alia* to identify proteins involved with human cancers, to elucidate components of multi-protein complexes, as well as for large-scale identification of proteins in organisms with fully sequenced genomes. Prior to MALDI-MS analysis, proteins/peptides are first separated by one-dimensional or two-dimensional polyacrylamide gel electrophoresis (1D or 2D-PAGE) or multidimensional liquid chromatography. Proteins/peptides are then identified by peptide mass mapping or fragment ion based database searching. Analytical procedures involving MALDI-MS are very robust, easy to automate, and most importantly, very fast both in terms of data acquisition and analysis.

However, peptide mass mapping may not routinely yield unambiguous protein identification with high confidence levels, particularly when only a few peptides are encountered. Furthermore, MALDI-MS often yields lower sequence coverage of proteins analyzed than electrospray ionization mass spectrometry (ESI-MS). This lower sequence coverage primarily results from both poor recovery of hydrophobic peptides during sample preparation and inefficient ionization of peptides without arginine residues by MALDI. In addition, MALDI-MS is intrinsically poor as a quantitation tool. Thus, it is very difficult to measure the relative abundance of proteins directly using MALDI-MS data.

There is a need in the art for additional reagents and methods for improving performance of MALDI-MS analysis of proteins/peptides both in terms of confident identification and accurate quantitation.

5

SUMMARY OF THE INVENTION

In one aspect, the invention provides a method for accurate relative quantitation of proteins using MALDI-MS. This method involves the following steps: reducing the disulfide bonds of proteins from a biological mixture; reacting the samples to be compared with a compound containing a guanidino group attached to a thiol reactive group via a linker which can be differentially labeled with either heavy
10 or light isotopes (optionally prior to or following reduction); separating the proteins from the mixture; digesting the proteins; and subjecting them to quantitative mass spectrometric analysis. The compounds of the invention are also well suited for enhancing ionization efficiency of cysteine-containing peptides by MALDI-MS. This
15 method is performed using the steps described above, with the following additional steps. The first sample is labeled with a reagent with isotopic substitutions and a second sample (e.g., a reference) is labeled with the equivalent reagent lacking these isotopic substitutions. Thereafter, the samples, or aliquots thereof, are mixed, prior to the separation step. After mixing, the modified proteins may be separated by 1D- or
20 2D-PAGE, gel bands or spots are cut and subjected to in-gel enzymatic digestion and subsequently MALDI-MS analysis. Alternatively, the mixed modified proteins may be subjected to enzymatic digestion and then the resulted peptides separated by various chromatographic steps before being subjected to MALDI-MS analysis. The proteins may be identified by peptide mass mapping or fragment-ion based data analysis and
25 the relative protein abundance may be obtained by analyzing the relative peak intensity or peak area of the same peptide from two different samples.

In another aspect, the invention also provides a method for accurate relative quantitation and identification of proteins analyzed by electrospray MS. This method is performed in a manner similar to the method described above.

In yet another aspect, the invention provides novel reagents and reagent kits containing the compounds of the invention.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

5

DETAILED DESCRIPTION OF THE INVENTION

The inventors have identified a number of problems that cause the ambiguous results in both identification and relative quantitation of proteins using conventional approaches involving gel electrophoresis, MALDI-MS, and peptide mass mapping.

10 More specifically, the inventors have found that the conventional 2D-PAGE/MALDI-MS/peptide mass mapping approach often provides inaccurate quantitation of proteins by gel image analysis and often ambiguous protein identifications. The inventors believe that poor ionization of certain peptides by MALDI is one of the main causes for ambiguous protein identifications. The present invention provides reagents and
15 methods which overcome the defects in conventional MALDI-MS and peptide mass mapping methods.

Advantageously, the reagents of the invention can be used as cysteine-alkylating reagents, which provide many more peptide peaks in MALDI-MS than reagents previously described for use in MALDI-MS. This increase in peptide peaks
20 observed when utilizing the reagents of the invention is due to the increased hydrophilicity and better ionization efficiency provided to the cysteine-containing peptides. Furthermore, because the methods of the invention utilize a mixture of light and heavy reagents, the exact number of cysteine residues in all peptide peaks observed by MALDI-MS can be determined. The resulting higher protein sequence
25 coverage (more peptides observed) together with the knowledge of the exact number of cysteine residues in all peptides observed greatly increases the specificity of database searching using peptide mass fingerprinting. In fact, this additional information can make peptide mass fingerprinting routinely yield confident protein identifications and therefore makes the MALDI-MS combined with peptide mass
30 fingerprinting a true high-throughput and yet unambiguous protein identification tool.

The higher protein sequence coverage also permits a more complete chemical modification map of proteins to be obtained. Furthermore, the differential labeling strategy improves the currently popular 2D-PAGE-MS or 2D-LC-MS approaches in proteomics by increasing the dynamic range and accurately quantifying individual
5 proteins. This improvement provides a much more complete picture of any proteome through the use of 2D-PAGE/2D-LC and MALDI-MS, thus increasing the possibility of finding protein drug targets that are differentially expressed in disease states.

Thus, the reagents of the invention are advantageous over conventional reagents for MALDI-MS analysis of proteins. These reagents can also be used for a
10 variety of other purposes. These reagents and uses therefore are described in more detail below.

Compounds With Guanidino Functional Groups



Cysteine-containing peptides are often more hydrophobic due to the fact that
15 disulfide bonds are usually buried inside of the globular proteins. Advantageously, the novel cysteine-modifying reagents of the invention not only increase the hydrophilicity of cysteine-containing peptides and thus minimize the loss of these hydrophobic peptides/proteins but also, more importantly, increase the ionization efficiency of these peptides by attachment of a guanidino functional group. Although
20 not limited to such a use, these compounds are particularly well suited for use in MALDI-MS analysis.

In one embodiment, the compounds of the invention (ICIER) has a formula of A1-Linker-A2 which comprises a reactive group (A1) attached to an ionization enhancement group (A2) via a linker which can be differentially labeled with stable
25 isotopes (Linker). Suitably, the ionization enhancement group is a strong basic functionality. In one embodiment, the ionization enhancement group (A2) is a guanidino group and has the formula: -NH-C(NH)-NH_2 .

The linker is any structure which may be differentially labeled with stable isotopes for use in quantitation and identification of proteins using MALDI-MS. In
30 one embodiment, the linker contain from 1 to 100 atoms in length, about 3 to about 50

atoms in length, or about 5 to about 15 atoms in length, which are composed of carbon, and optionally, one or two atoms selected from O, S, NH, NR, NR', CO, C(O)O, C(O)S, S-S, SO₂, C(O)-NR', CS-NR', or Si-O. Optionally, one or more of the C atoms may be substituted with a small alkyl (C₁-C₆), alkenyl, alkoxy, aryl, or
5 diaryl groups. For example, the linker may be an alkyl, alkenyl, or alkynyl group, optionally substituted as described above. In another example, the linker may itself contain one or more O, S, NH, NR, NR', CO, C(O)O, C(O)S, S-S, SO₂, C(O)-NR', CS-NR', Si-O groups bound to one or more C atoms, which may be optionally substituted. In one embodiment, the linker is an alkyl group which contains a
10 substitution of about four to about twelve atoms with a stable isotope. However, the linker may contain more than six isotope substitutions where desirable. For example, for peptides at the higher end of the molecular weight range at which MS is useful (e.g., about 2000 Da to 3500 Da) it may be desirable for the linker to contain eight, ten, twelve or more substitutions, in order to achieve the differential analysis required;
15 whereas peptides at the lower end of the molecular weight range for MS (e.g., about 500 to 2000 Da) may require only four to six substitutions. For the selected number of substitutions, any one or more of the hydrogen, nitrogen, oxygen, carbon, or sulfur atoms in the linker may be replaced with their isotopically stable isotopes: ²H, ¹³C, ¹⁵N, ¹⁷O, ¹⁸O, or ³⁴S.

20 The reactive group A1 reacts, preferably specifically, with thiols, and more particularly, with cysteine residues. Desirably, the thiol-reactive group is selected from the group consisting iodide, maleimide (see, for example, the structures below)




25

and

or α -haloacetyl groups such as $X-CH_2CO-$. Most suitably, the X is selected from halogens such as iodine, bromine, and chlorine to form iodoacetyl, bromoacetyl, or chloroacetyl functionalities.


In another alternative, the thiol-reactive group may be selected from other α -,
 5 β -conjugated double bond structures, such as



and the like. Still other reactive groups can be readily synthesized to contain other
 10 thiol-specific reactive groups for use in binding cysteine-containing peptides.


In certain preferred embodiments, a compound of the invention (ICI_{ER}) comprises a thiol-reactive group attached to a guanidino group by a linker, in which the formula of the compound is:

15 Reagent A:




20

Reagent B:




25


Reagent C:



Reagent C':



Reagent D:



While Compound C' (one example of heavy ICIER) represents one particularly desirable isotopically heavy substituted version of Compound C (one example of Light ICIER), other isotopically heavy versions of this formula may be readily produced according to the present invention. Similarly, a variety of substitutions to Compounds A, B and D may be readily generated by one of skill in the art based on the teachings provided herein.

Synthesis of Reagents

The compounds of the invention may be readily synthesized by one of ordinary skill in the art utilizing the methods described in the examples below and

techniques known to those of skill in the art. Some exemplary methods are illustrated in Example 1 below.

For example, a suitable starting material may be mixed with L-arginine in a mixture of tetrahydrofuran (THF) and water in a ratio of about 1 to about 1 parts by volume, for about 10 to about 48 hours, and most preferably about 16 hours at room temperature. The reaction mixture is then poured into acetone and the solid is collected. The solid is then dissolved in water and introduced into a suitable column, which is eluted with water to provide a compound of the invention. However, the invention is not so limited. For example, other suitable solvents may be substituted for the THF or acetone. Alternatively, the ratio of THF to water may be adjusted, as needed or desired. As another example, a salt of L-arginine (e.g., L-arginine D7-hydrochloride or L-argininamide dihydrochloride) may be dissolved in water and the pH adjusted to the basic range (e.g., about 8 to about 13, and more preferably about 8 to about 10), prior to reaction with iodoacetyl anhydride. Thereafter, the solid may be collected, e.g., by lowering the pH to the acid range (e.g., about 2 to about 4), filtering the resin and extracting the aqueous solution, followed by further filtration. The resulting solid may be freeze-dried to yield the desired compound.

However, given the descriptions provided herein, one of skill in the art will be able to readily select appropriate techniques and reagents for synthesis of compounds of the invention.

Following synthesis, the compounds are preferably purified to achieve the best results, particularly when they will be used in conjunction with 2D-PAGE, since reagents made *in situ* contain an excess of salt that will interfere with the first separation step of isoelectric focusing. Suitably, purification may be performed by filtration. Alternatively, other suitable methods may be readily selected by one of skill in the art.

These compounds may be utilized in a variety of methods in which protein/peptide labeling and/or increasing the ionization of cysteine-containing peptides is desired. However, the compounds are particularly useful in methods for high-throughput protein identification and quantitation using MALDI-MS.

Methods of Using the Compounds of the Invention

The compounds of the invention are particularly useful in methods for quantitation and identification of one or more proteins in a mixture. Suitably, the peptides analyzed by the method of the invention are between about 500 Daltons (Da) to about 3500 Daltons. The protein mixture may be a sample from a cell or tissue culture, or biological fluids, cells or tissues. Samples from a culture include cell homogenates and cell fractions. Biological fluids include urine, blood (including, e.g., whole blood, plasma and sera), cerebrospinal fluid, tears, feces, saliva, and lavage fluids. The mixtures may include proteins, lipids, carbohydrates, and nucleic acids. The methods of the invention employ MS and (MS)ⁿ methods. Currently, matrix assisted laser desorption ionization MS (MALDI/MS) and electrospray ionization MS (ESI/MS) methods are preferred. However, a variety of other MS and (MS)ⁿ techniques may be selected.

In one embodiment, the invention provides a method for quantitative analysis of a proteome (i.e., a complex mixture containing proteins and/or peptides) using the compound of the invention. Typically, a sample is obtained from a source, as defined above. Where isolated proteins will be identified using techniques based on MALDI-MS and peptide mass mapping, the sample may be compared to a reference protein mixture, which is obtained as a sample from the same source or may be obtained from another source. Alternatively, isolated proteins may be identified using post-source delay (PSD) or collision-induced dissociation (CID) techniques followed by fragment ion-based database searching (M. Mann and M. Wilm, *Anal. Chem.*, 66: 4390 (1994)) or *de novo* sequencing, and the sample may be compared to a reference protein mixture using MS data. The sample protein mixture and the reference protein mixture are processed separately, applying identical reaction conditions, with the exception that only one mixture (e.g., the sample) will be reacted with the compound containing isotopically stable isotopes. Alternatively, where relative quantitation of proteins is not desirable, no reference samples are required; nor are isotopically heavy equivalents of the compounds of the invention required. Optionally, any labeling

reaction step may be performed prior to, or following the other method steps which are described herein.

Typically, the protein sample is dissolved in a buffer suitable for 1D-PAGE or 2D-PAGE or in-solution enzymatic digestion. Such buffers may be purchased
5 commercially from a variety of sources (e.g., Genomic Solutions, Ann Arbor, MI; BioRad, Hercules, CA) or prepared according to known methods. Throughout the following method steps, the pH of the mixture is maintained under neutral or basic conditions. Most suitably, the pH is maintained between 7 and 10. Preferably, the method of the invention is performed at a basic pH where the compound of the
10 invention containing the guanidino group (e.g., compounds A, B, C, C' and D) is utilized. Most suitably, the pH is in the range of about 8 to about 9, and most preferably about 8.5. Alternatively, the method of the invention is preferably performed at a neutral pH where a compound of the invention containing a maleimide affinity tag is utilized. In this circumstance, the method is preferably performed at a
15 pH of about 6.5 to about 8.5, more preferably 7 to 8, and most preferably 7 to 7.5.

Following preparation of the sample and reference, the disulfide bonds of the proteins in the sample(s) or reference mixtures are reduced to free SH groups. Suitable reducing agents include tri-n-butylphosphine, mercaptoethylamine, dithiothreitol (DTT), and tricarboxyethylphosphine, which are used in excess.
20 However, other suitable reducing agents may be substituted. In one embodiment, disulfide bonds are denatured using 50 mM Tris buffer, 6M guanidine HCl, 5 mM tributyl phosphine at pH 8.5 for 1 hour at 37°C. However, other reducing agents, buffered to a pH in the basic range may be selected and incubated for varying lengths of times at room temperature.

25 Where no protein quantitation is to be performed, no reference sample need be labeled, and the following parallel reaction steps with equivalent heavy or light ICIER and mixing steps can be eliminated. Where protein quantitation will be performed, a selected compound of the invention, either an isotopically heavy or light compound, will be reacted with the samples to be compared. This labeling reaction step may be
30 performed prior to, or following the other method steps which are described herein.

Typically, the reference sample is labeled with the isotopically heavy compound and the experimental sample(s) are labeled with the isotopically light form of the compound. However, the labeling may be reversed. Following reduction and reaction with the selected labeling reagents (heavy or light ICIER), defined aliquots of the samples (optionally labeled with isotopically different compounds, e.g., corresponding light and heavy compounds) are combined and all the subsequent steps are performed on the pooled samples. Preferably, equal amounts of the samples are combined.

Suitably, prepared gels for one-dimensional (1D) or two-dimensional (2D) polyacrylamide gel electrophoresis (PAGE) may be obtained from a variety of commercial sources and used according to manufacturer's instruction (Genomics Solutions; Ann Arbor, MI; NOVEX, San Diego, CA). However, the invention is not so limited. One of skill in the art can readily apply other techniques for separating the ICIER-labeled proteins.

Following mixing of the ICIER-treated samples, the proteins are separated by 1D-PAGE or 2D-PAGE. Then the protein bands or spots of interest are cut and subjected to enzymatic digestion. Suitably, the proteins may be subjected to in-gel digestion using techniques which have been described previously (e.g., Rosenfeld et al, *Anal. Biochem.*, **203**:173-179 (1992) and Sechi et al, *Anal. Chem.*, **70**:5150-5158 (1998)), or the modification thereof as described in the examples below.

A suitable protease for use in this enzymatic digestion method may be readily selected from among proteases which are compatible with the basic conditions and the procedure. In one embodiment, the protease is trypsin. In another embodiment, a mixture of proteases which have similar activity levels at basic pH is used. Such proteases may include aminopeptidases, carboxypeptidases, among others. Alternatively, protein digestion may be omitted where the proteins to be analyzed are small (e.g., about 500 to 1000 Da).

Suitably, the peptides are extracted from the gel using conventional techniques. For example, following destaining, the peptides may be extracted by adding a solution of acetonitrile and trifluoroacetic acid (TFA) to the gel band and

incubating, before collecting the liquid phase. This step may be repeated and additional acetonitrile added to complete the extraction. The extract solutions are pooled and dried, then reconstituted with a solution of acetonitrile and TFA. Other suitable methods for peptide extraction are well known to those of skill in the art and
5 may be readily utilized.

The isolated, derivatized peptides are then analyzed using MS techniques. Both the relative quantity and sequence identity of the proteins from which the labeled peptides originated can be determined by MALDI-MS techniques (i.e. MS and MSⁿ(PSD, CID)) and subsequent data analysis (i.e. peptide mass mapping or
10 fragment-ion based data analysis). Preferably, the relative quantitation of proteins is obtained from MS data, while the protein identification can be derived from the analysis of either MS data (peptide mass mapping) or MSⁿ data (fragment ion based database searching).

Apparatuses for performing MALDI-MS, and techniques for their use, are
15 described in International Publication WO 93/24835, US Patent 5,288,644, R. Beavis and B. Chait, *Proc. Natl. Acad. Sci. USA*, **87**:6873-6877 (1990); B. Chait and K. Standing, *Int. J. Mass Spectrom. Ion Phys.*, **40**:185 (1981) and Mamyrin et al, *Sov. Phys. JETP*, **37**:45 (1973), all of which are incorporated by reference herein. Briefly, the frequency tripled output of, e.g., a Q-switched Lumonics HY400
20 neodymium/yttrium aluminum garnet laser ("Nd-YAG") (355 nm, 10-nsec output pulse) is focused by a lens (12-inch focal length) through a fused silica window onto a sample inside the mass spectrometer. The product ions formed by the laser are accelerated by a static electric potential of 30 kV. The ions then drift down a 2-m tube maintained at a vacuum of 30 μ Pa and their arrival at the end of the tube is
25 detected and recorded using, e.g., a Lecroy TR8828D transient recorder. The transient records of up to 200 individual laser shots are summed together and the resulting histogram is plotted as a mass spectrum. Peak centroid determinations and data reduction can be performed using a VAX workstation or other computer system.

However, other MS techniques, including electrospray ionization (ESI)/MS, among others, may be readily utilized to analyze the proteins and peptides modified by the compounds of the invention (ICIER).

5 *Reagent Kit*

The invention further provides a reagent kit for the analysis of proteins by mass spectral analysis. Typically, such a kit will contain one or more compounds of the invention. Most suitably, the kit will contain a set of substantially identical, differentially labeled (isotopically light and heavy) compounds. The kit may further
10 contain one or more proteolytic enzymes, reaction buffers, or wash solutions.

The method and kit of the invention may be used for a variety of clinical and diagnostic assays, in which the presence, absence, deficiency or excess of a protein is associated with a normal or disease state. The method and kit of the invention can be used for qualitative and quantitative analysis of protein expression in cells and tissues.
15 The method and kit can also be used to screen for proteins whose expression levels in cells or biological fluids is affected by a drug, toxin, environmental change, or by a change in condition or cell state, e.g., disease state, malignancy, site-directed mutation, gene therapy, or gene knockouts.

20 The following examples are provided to illustrate the invention and do not limit the scope thereof. One skilled in the art will appreciate that although specific reagents and conditions are outlined in the following examples, modifications can be made which are meant to be encompassed by the spirit and scope of the invention.

25

EXAMPLE 1: REAGENTS OF THE INVENTION

This example illustrates methods for synthesis of exemplary compounds A, B, C, C' and D of the invention. These compounds are useful as reagents in MALDI-MS and peptide mass mapping, as shown in the following examples.

5 1. **2-(2-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-acetyl-amino)-5-guanidino-pentanoic acid or maleimidoacetyl arginine (A):**

(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-acetic acid-2,5-dioxo-pyrrolidin-1-yl ester (4.8 g, 19 mmol) and L-arginine (2.9 g, 17 mmol) was stirred in 30 mL of a mixture of tetrahydrofuran (THF) and water, THF:H₂O (1:1), for 16 hours at room temperature. The reaction mixture was poured into acetone (1.5 L) and the solid was collected. The solid was dissolved in H₂O (3 mL) and then introduced onto Bakerbond (Octadecyl (C18) 40 µm prep LC Packing) column, and eluted with water to give 1.1 g of product. ¹H NMR (D₂O, 300 MHz): 6.8 (s, 2H), 4.3 (H_a, d, J = 16.9 Hz, 1H), 4.2 (H_b, d, J = 16.9 Hz, 1H), 4.1 (dd, J = 4.9, 7.7 Hz, 1H), 3.1 (t, J = 6.9 Hz, 2H), 1.8-1.5 (m, 4H).

15 2. **2-(3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionyl-amino)-5-guanidino-pentanoic acid or Maleimidopropionyl arginine (B):**

3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionic acid-2,5-dioxo-pyrrolidin-1-yl ester (7.6 g, 28.5 mmol) and L-arginine (4.3 g, 25 mmol) was stirred in 50 mL of a mixture of THF:H₂O (1:1) for 16 hr at room temperature. The reaction mixture was poured into acetone (1.5 L) and the solid was collected. The solid was dissolved in H₂O (5 mL) and then introduced onto Bakerbond (Octadecyl (C18) 40 µm prep LC Packing) column, and eluted with water to give 1.5 g of product. ¹H NMR (D₂O, 300 MHz): 6.8 (s, 2H), 4.1 (dd, J = 4.7, 7.4 Hz, 1 H), 3.8 (m, 2H), 3.2 (t, J = 6.9 Hz, 2H), 2.5 (m, 2H), 1.7-1.5 (m, 4H).

25 3. **N-α-(Iodoacetyl)-L-arginine (C):**

L-Arginine (8.0 g, 45.6 mmol) was dissolved in deionized water (75 mL) and was reacted with iodoacetic anhydride (21.0 g, 59.3 mmol) with vigorous stirring for 15 min while the pH was maintained between 8 and 9.5 with Dowex 1x2-100 (OH⁻). The pH was allowed to drop to ~4 (5-10 min) and 55% aqueous

hydriodic acid was added to bring the pH to 2. The resin was filtered and the aqueous hydriodic acid was extracted with diethyl ether (3 x 250 ml). The aqueous layer was neutralized with Dowex 1x2-100 (OH⁻) to pH 8-9, the resin was filtered and washed with water and the resulting solution was freeze-dried to afford N- α -(Iodoacetyl)-L-arginine (11.9 g, 76% overall yield) as a fluffy white powder. ¹H NMR (D₂O) δ 1.52-1.88 (m, 4H), 3.12 (t, 2H, J = 6.7 Hz), 3.76 (d, 1H, J = 10.2 Hz), 3.76 (d, 1H, J = 10.4 Hz), 4.06-4.10 (m, 1H); ¹³C NMR (D₂O) δ 2.0, 24.5, 28.8, 40.7, 55.1, 156.8, 171.5, 178.3. Molecular formula: C₁₈N₁₅N₄IO₃.

4. **N- α -(Iodoacetyl)-L-arginine-D₇ (C'):**

L-arginine-D₇ hydrochloride (5.2 g, 28.73 mmol) was dissolved in deionized water (50 mL) and the pH was adjusted to 8 with Dowex 1x2-100 (OH⁻). It was then reacted with iodoacetic anhydride (15.5 g, 43.78 mmol) as above to afford N- α -(Iodoacetyl)-L-arginine-D₇ (5.5 g, overall yield 55%) as a fluffy white powder. ¹H NMR (D₂O) δ 3.74 (d, 1H, J = 10.2 Hz), 3.82 (d, J = 10.4 Hz). Molecular formula: C₈H₈D₇N₄IO₃.

5. **N- α -(Iodoacetyl)-L-argininamide hydrochloride (D):**

L-Argininamide dihydrochloride (10.5 g, 42.6 mmol) was dissolved in deionized water (75 mL) and the pH was adjusted to 13 with Dowex 1x2-100 (OH⁻). Then it was reacted with iodoacetic anhydride (18.0 g, 50.85 mmol) with vigorous stirring for 15 min while the pH was maintained between 8 and 9.5 with Dowex 1x2-100 (OH⁻). The pH was allowed to drop to ~4 (5-10 min) and 55% aqueous hydriodic acid was added to bring the pH to 2. The resin was filtered and the aqueous solution was extracted by diethyl ether (3x250 ml). The aqueous layer was filtered through a pad Dowex Retardion 11A8 (50g) and washed with water. The resultant solution was freeze-dried to afford N- α -(Iodoacetyl)-L-argininamide hydrochloride (11.1 g, 69%) as a fluffy white powder. ¹H NMR (D₂O) δ 1.62-2.02 (m, 4H), 3.24 (t, 2H, J = 6.6 Hz), 3.79 (d, 1H, J = 10.2 Hz), 3.89 (d, 1H, J = 10.7 Hz), 4.27-4.31 (m, 1H); ¹³C NMR (D₂O) δ 2.7, 24.5, 28.3, 40.6, 53.6, 156.9, 172.5, 176.3. Molecular formula: C₈H₁₆N₅IO₂.HCl.

EXAMPLE 2 - COMPARATIVE EXAMPLE DEMONSTRATING IONIZATION
ENHANCEMENT - MALDI-MS ANALYSIS OF SIX SEPARATE MODEL
PROTEINS AFTER TREATMENT WITH EITHER THE REAGENT OF THE
INVENTION (LIGHT ICIER) OR A CONVENTIONAL REAGENT (IAA).

5 A. **Reduction:**

90 µg each of the six model proteins, CTLA-4-IgG1, Interleukin-12
(IL-12), α-Lactalbumin, Trypsinogen, Lysozyme, and Ribonuclease, were dissolved
separately in 30 µL of the reaction buffer containing 5% SDS, 20% glycerol, and 750
mM Tris-HCl (pH 8.45) to obtain solutions of 3 µg/µL. To each solution was added a
10 200-fold excess (with regard to cysteine content per protein) of dithiothreitol (DTT).
The reduction was allowed to proceed for 30 minutes at 90°C, followed by cooling of
the solutions for 10 minutes.

 B. **Cysteine Modification:**

Reagent C (light ICIER) was synthesized as described in Example 1.
15 Each of the six proteins was alkylated using both reagent C and iodoacetamide
separately. The amount of the alkylating reagent (reagent C or iodoacetamide) was
equivalent to a five-fold excess with regard to the amount of DTT used in step A.
The alkylations were allowed to proceed for 1 hour at room temperature. Then 0.1 µg
of each protein labeled by reagent C was mixed with 0.1 µg of the same protein but
20 alkylated by iodoacetamide. Each of the six resultant protein solutions was then
mixed in a 1:1 ratio (volume to volume) with 2X Tricine loading buffer.

 C. **Gel Electrophoresis and Staining:**

Each of the final resultant protein solutions described in Part B (each
solution contains 0.2 µg of one of the six proteins) was loaded onto a 10%, 10-well
25 Tricine mini-gel (Novex, San Diego, CA). The gels were run according to the
manufacturer's instructions and stained with Coomassie Blue G-250.

 D. **In-gel Digestion:**

Automated in-gel digestion of proteins was carried out using a 96-well
ProGest (Genomic Solutions, Ann Arbor, MI) with a procedure modified from

Rosenfeld et al, *Anal. Biochem.*, **203**:173-179 (1992) and Sechi et al, *Anal. Chem.*, **70**:5150-5158 (1998). Briefly, gel bands were cut into 1x1 mm pieces and then destained by washing sequentially with 50 μ L each of the following solutions: (1) 200 mM NH_4HCO_3 , (2) 50% methanol/10% acetic acid; (3) 40% ethanol/water and
5 incubated for 10 minutes for each step. The three washing steps were repeated 5 times and then 100 μ L of 10 mM NH_4HCO_3 was added and incubated for 10 minutes. The gel pieces were then dehydrated by addition of 2x100 μ L of acetonitrile. After removing the excess acetonitrile, the gels were rehydrated with 25 μ L of a solution containing 625 ng of trypsin in 10 mM NH_4HCO_3 and incubated at 37°C for 10 hours.
10 Peptides were extracted by adding 30 μ L of a solution of 50% acetonitrile/0.5% trifluoroacetic acid (TFA) and incubated for 10 minutes before collecting the liquid phase. This step was repeated one more time and then 30 μ L of acetonitrile was added to complete the extraction. The extracted solutions were pooled together and dried completely with a SpeedVac (Savant, Holbrook, NY). Finally, the dried peptide
15 samples were reconstituted with 20 μ L of an acetonitrile/water/TFA (50:50:1) solution.

E. MALDI Mass Spectrometry

Molecular weights of all peptides were determined by analyzing one-twentieth of the reconstituted peptide solution employing a matrix-assisted laser
20 desorption ionization (MALDI) delayed extraction (DE) reflectron time-of-flight (TOF) instrument (Voyager DE-STR, PE Biosystems, Framingham, MA) equipped with a nitrogen laser (337 nm) in reflectron mode. Peptides were crystallized by mixing 0.8 μ L of the sample solution with 0.8 μ L of a matrix solution containing saturated α -cyano-4-hydroxycinnamic acid in 0.5% TFA/50% acetonitrile/water.
25 Spectra were externally calibrated using a mixture of known peptides.

Peak tables were generated from each spectrum and the data were used to create the ionization enhancement and peak ratio tables presented herein.

The following tables summarize the results of the MALDI-MS analysis of the six protein samples after treatment with reagent C (ICIER) or iodoacetamide
30 (IAA) and the comparison of the same. See Tables I-XVIII.

Table I

CTLA4- alkylated with IAA 1:1 (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1161.6112	1161.6302	1991
N/A	1171.5491	N/A
1187.5239	1187.5441	1452
1485.7119	1485.7048	7944
2138.9793	2139.028	7551
2801.3180	2801.2677	1253
2817.9851*	2817.2626	1567
Theoretical Number of Cysteines: 11		
Number of Cysteines Detected: 5		

Table II

CTLA4-IgG alkylated with Reagent C (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1318.7222	1318.7153	10610
1328.6746	1328.6343	3035
1344.6331	1344.6292	3922
1642.7809	1642.7899	22134
2296.0863	2296.1131	8587
2958.3574	2958.3528	1442
2974.3377	2974.3477	1210
Theoretical Number of Cysteines: 11		
Number of Cysteines Detected: 5		

Table III

Comparison of Data for CTLA4-IgG		
Height Ratio for CTLA4-IgG (Reagent C/IAA)	Peptide Sequence	SEQ ID NO:
5.33	(K)NQVSLTCLVK(G)	1
N/A	(R)AMDTGLYICK(V)	2
2.70	(R)AMDTGLYICK(V)	2
2.79	(R)GIASFVCEYASPGK(A)	3
1.14	(R)TPEVTCVVVDVSHEDPEVK(F)	4
1.15	(R)WQQGNVFSCSVMHEALHNHYTQL(S)	5
0.77	(R)WQQGNVFSCSVMHEALHNHYTQK(S)	5

Table IV

IL-12 alkylated with IAA (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
N/A	907.4671	N/A
1412.5917	1412.5905	6566
N/A	1795.7274	N/A
1863.8916	1863.8507	6089
2206.1381	2206.0895	782
Theoretical Number of Cysteines: 9		
Number of Cysteines Detected: 3		

Table V

IL-12 alkylated with Reagent C (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1064.5402	1064.5523	2411
1569.7046	1569.6756	9028
1952.8747	1952.8125	5441
2020.9710	2020.9358	4543
2363.2748	2363.1746	1181
Theoretical Number of Cysteines: 9		
Number of Cysteines Detected: 5		

5

Table VI

Comparison of Data for IL-12		
Height Ratio for IL-12 (Reagent C/IAA)	Peptide Sequence	SEQ ID NO:
N/A	(K)TSATVICR(K)	6
1.37	(K)EFGDAGQYTCHK(G)	7
N/A	(R)YYSSSWSEWASVPCS(-)	8
0.75	(R)GSSDPQGVTCTGAATLSAER(V)	9
1.51	(R)FTCWVLTITISTDLTFSVK(S)	10

Table VII

α-Lactalbumin alkylated with IAA (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
none	707.3398	N/A
1091.51432	1091.5196	6131
none	1715.7508	N/A
1779.83739	1779.8410	3436
none	1843.8458	N/A
1892.92914	1892.9250	7606
2003.914	2003.8187	overlap
2591.27206	2591.1077	3115
Theoretical Number of Cysteines: 8		
Number of Cysteines Detected: 5		

Table VIII

α-Lactalbumin alkylated with Reagent C (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
864.42181	864.4249	6976
1248.60859	1248.6047	33460
1872.83547	1872.8359	17483
2093.96824	2094.0112	3307
2000.93299	2000.9309	11339
2207.10324	2207.0953	7629
2317.96953	2317.989	5207
none	3062.3631	N/A
Theoretical Number of Cysteines: 8		
Number of Cysteines Detected: 7		

Table IX

Comparison of Data for α -Lactalbumin		
Height Ratio for α -Lactalbumin (Reagent C/IAA)	Peptide Sequence	SEQ ID NO:
N/A	(K)ALCSEK(L)	aa 1-8 of SID NO:11
5.46	(K)LDQWLCEK(L)	aa 7-16 of SID NO:11
N/A	(K)FLDDDLTDDIMCVK(K)	aa1-16 of SID NO:12
0.96	(K)ALCSEKLDQWLCEK(L)	11
N/A	(K)FLDDDLTDDIMCVKK(I)	12
1.00	(K)ALCSEKLDQWLCEKL(-)	11
N/A	(K)DDQNPSSNICNISCDK(F)	aa5-23 of SID NO:12
N/A	(K)IWCKDDQNPSSNICNISCDK(F)	13

Table X

Lysozyme alkylated with IAA (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
N/A	505.2557	N/A
none	577.2880	N/A
993.4044	993.4001	16094
1065.4958	1065.5185	5466
1325.6148	1325.6312	7685
1333.6643	1333.6687	25788
N/A	1491.6552	Buried
2181.0465	2181.0300	8876
2508.5231	2508.29788	2902
2735.4461	2735.2636	2672
Theoretical Number of Cysteines: 9		
Number of Cysteines Detected: 5		

Table XI

Lysozyme alkylated with Reagent C (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
662.3187	662.3408	11061
734.3755	734.3732	2407
1150.4807	1150.4852	9782
1222.5917	1222.6036	9199
1428.6595	1428.7164	56959
1490.7545	1490.7538	24700
1648.7478	1648.7403	8750
2338.1091	2338.1151	5656
2979.3921	2979.4450	1867
2892.4820	2892.3487	2113
Theoretical Number of Cysteines: 9		
Number of Cysteines Detected: 8		

Table XII

Comparison of Data for Lysozyme		
Height Ratio for Lysozyme (Reagent C/IAA)	Peptide Sequence	SEQ ID NO:
N/A	(R)GCRL(-)	14
N/A	(R)NRCK(G)	15
0.61	(R)WWCNDGR(T)	aa1-9 of SID NO:18
1.68	(R)CELAAAMKR(H)	16
7.41	(R)GYSLGNWVCAAK(F)	aa1-14 of SID NO:21
0.96	(R)CKGTDVQAWIR(G)	17
N/A	(R)WWCNDGRTPGSR(N)	18
0.64	(R)HGLDNYRGYSLGNWVCAAK(F)	19
0.64	(R)NLCNIPCSALLSSDITASVNCAK(K)	20
0.79	(R)GYSLGNWVCAAKFESNFNTQATNR(N)	21

Table XIII

Ribonuclease A alkylated with IAA (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1504.6742	1504.6825	6041
2224.0861	2224.1065	22526
2517.2230	2517.2890	14079
2867.4150	2867.5666	4222
Theoretical Number of Cysteines: 8		
Number of Cysteines Detected: 4		

Table XIV

Ribonuclease A alkylated with Reagent C (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1661.7593	1661.7785	16953
2381.1712	2381.1743	46801
2831.3933	2831.3889	9332
3024.5002	3024.7205	4879
Theoretical Number of Cysteines: 8		
Number of Cysteines Detected: 5		

5

Table XV

Comparison of Data for Ribonuclease		
Height Ratio for Ribonuclease (Reagent C/IAA)	Peptide Sequence	SEQ ID NO:
2.81	(R)ETGSSKYPNCAYK(T)	22
2.08	(K)HIIVACEGNPYVPVHFDASV(-) aa7-27 of SIDNo:24	
0.66	(R)CKPVNTFVHESLADVQAVCSQK(N)	23
1.16	(K)TTQANKHIIVACEGNPYVPVHFDASV(-)	24

Table XVI

Trypsinogen alkylated with IAA (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1168.59697	1168.5825	5577
none	1077.5250	N/A
none	1478.7347	N/A
1490.75058	1490.7426	4891
1609.68206	1609.6586	1573
none	2267.0110	N/A
Theoretical Number of Cysteines: 12		
Number of Cysteines Detected: 3		

Table XVII

Trypsinogen alkylated with Reagent C (1:1 @ 0.1 g/band)		
Detected Mass (Da)	Theoretical Mass (Da)	Height
1325.68371	1325.6676	24135
1234.6102	1234.61265	12845
1792.94896	1792.9050	2455
1647.85269	1647.8277	14787
1923.88166	1923.8289	2795
2424.06382	2424.0964	3046
Theoretical Number of Cysteines: 12		
Number of Cysteines Detected: 7		

Table XVIII

Comparison of Data for Trypsinogen		
Height Ratio for Trypsinogen (Reagent C/IAA)	Peptide Sequence	SEQ ID NO:
4.33	(K)VCNYVSWIK(Q)	25
N/A	(K)APILSDSSCK(S)	26
N/A	(K)CLKAPILSDSSCK(S)	27
3.02	(K)LQGIVSWGSGCAQK(N)	28
1.78	(K)DSCQGDSGGPVVCSGK(L)	29
N/A	(K)SAYPGQITSNMFCAGYLEGGK(D)	30

From these data, it was concluded that, compared to the conventional cysteine-alkylating reagent Iodoacetamide, ICIER greatly increases the ionization efficiency of cysteine-containing tryptic peptides with a lysine residue at their C-terminus. For example, in the MALDI-MS spectrum of tryptic peptides from lysozyme modified by both reagent C and IAA (see Table XII), the intensity of a peptide modified by reagent C (GYSLGNWVCAAK, aa 2 – 13 of SEQ ID NO:21, molecular weight, 1428.72 Da) is 7.4 times that of the same peptide modified by IAA (molecular weight, 1325.63 Da). Moreover, mass peaks for many cysteine-containing peptides with a lysine residue at their C-terminus that were absent when using IAA became well observed when using ICIER. On the other hand, ICIER modification did not have any significant effect on the ionization of peptides with an arginine residue at their C-terminus. As a result, the overall number of cysteine-containing peptides detected by MALDI-MS is also increased, and hence the sequence coverage obtained for proteins being analyzed when using ICIER is much higher than that when using iodoacetamide.

EXAMPLE 3 – PROTEIN QUANTITATION BY ICIER AND MALDI-MS USING CTLA4-IgG AS A MODEL PROTEIN

Different amounts of CTLA4-IgG with ratios of 1:1, 1:1.5, 1:2, 1:5, and 1:10 were reduced by DTT as described in EXAMPLE 2. The samples to be compared were alkylated with either light or heavy ICIER and then mixed together before being subjected to gel electrophoresis, protein staining, in-gel digestion, and MALDI-MS analysis using the same conditions described in EXAMPLE 2.

Table XIX summarizes the labeling of CTLA4-IgG at different ratios using light and heavy ICIER. Peptide masses were all externally calibrated using default calibration files. The relative quantitation of the protein from two different pools was determined by averaging the mass intensity ratios between all seven pairs of peptides labeled by light and heavy ICIER.

Table XIX

Theor. Mass (Da)	Peptide Sequence	SEQ ID NO:	Observed Ratios*				
1318.72	(K)NQVSLTCLVK(G)	1	<u>1.23</u>	<u>1.64</u>	<u>2.29</u>	<u>4.22</u>	<u>8.9</u>
1328.63	(R)AMDTGLYICK(V)	2	<u>0.88</u>	<u>0.62</u>	<u>1.43</u>	<u>0.61</u>	<u>0.7</u>
1374.63	(R)AMDTGLYICK(V)	2	0.95	1.39	2.01	4.31	8.2
1642.79	(R)GIASFVCEYASPGK(A)	3	0.96	1.39	1.86	3.68	10
2296.11	(R)TPEVTCVVVDVSHEDPEVK(F)**	4	1.02	1.52	2.3	4.62	8.6
2958.35	(R)WQQGNVFSCSVMHEALHNHYTQK(S) 5		<u>0.88</u>	<u>0.84</u>	<u>1.61</u>	<u>2.88</u>	<u>2.9</u>
2974.35	(R)WQQGNVFSCSVMHEALHNHYTQK(S) 5		<u>0.72</u>	1.59	2.18	5.01	11
Mean of the Observed Ratio			1.04	1.47	2.09	4.41	9.38
Expected Ratio			1	1.5	2	5	10
Standard Deviation			0.04	0.1	0.19	0.56	1.2
% Error			4	1.83	4.38	11.9	6.25

In Table XIX, * indicates observed ratio values. Underlining indicates poor quality or overlapping peaks. These values were not included in the statistical calculation.

From these data, it was illustrated that the observed ratios closely reflect the
5 expected ratios of light to heavy ICIER labeled peptides, especially when mass peaks that give very weak intensity or overlap with other mass peaks were excluded. The percentage error of quantitation using the ICIER approach is less than 12% for all ratios which is very accurate in contrast to densitometry. Furthermore, the ICIER approach is also capable of quantifying multiple proteins in a single sample, gel band
10 or spot since the quantitation is based on peptides with known sequence identity.

From these data, it was also concluded that with the use of a mixture of light and heavy ICIER, an exact number of cysteine residues contained in each detected MS peak can be determined based on the presence or absence of the isotopically labeled pairs without extra sample manipulation (see TABLE XX). This additional
15 information can be readily used with peptide masses for a more constrained peptide mass mapping to give confident protein identification. This is particularly useful when dealing with more than one protein in an analysis or only a limited number of mass peaks.

Table XX. Identification of the exact number of cysteine residues in each MS peaks


Experimental Mass (Da)	Exact Number of Cysteines	Sequence of Cysteine-Containing Peptides Derived from CTLA4-IgG : SEQ ID NO:
587.1578	0	
951.2411	0	
1286.6826	0	
1318.6902	1 - light	(K)NQVSLTC*LVK(G) 1
1325.6597	1 - heavy	(K)NQVSLTC**LVK(G) 1
1344.7691	1 - light	(R)AM*DTGLYIC*K(V) 2
1351.6682	1 - heavy	(R)AM*DTGLYIC**K(V) 2
1481.7472	0	
1642.8055	1 - light	(R)GLASFVC*EYASPGK(A) 3
1649.9140	1 - heavy	(R)GLASFVC**EYASPGK(A) 3
1677.6275	0	
1689.7607	0	
1807.8651	0	
1872.8749	0	
2296.0488	1 - light	(R)TPEVTC*VVVDVSHEDPEVK(F) 4
2303.1326	1 - heavy	(R)TPEVTC**VVVDVSHEDPEVK(F) 4
2958.8857	1 - light	(R)WQQGNVFSC*SVMHEALHNHYTQK(S) 5
2965.5758	1 - heavy	(R)WQQGNVFSC**SVMHEALHNHYTQK(S) 5
2974.3697	1 - light	(R)WQQGNVFSC*SVM*HEALHNHYTQK(S) 5
2981.1270	1 - heavy	(R)WQQGNVFSC**SVM*HEALHNHYTQK(S) 5
3336.6515	0	

Abbreviations: C*, cysteine residue labeled by light ICIER; C**, cysteine residue labeled by heavy ICIER; M*, oxidized methionine.


All publications cited in this specification are incorporated by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall
5 within the scope of the appended claims.

WHAT IS CLAIMED IS:


1. A method for enhancing identification and relative quantitation of proteins and peptides using mass spectrometry (MS), said method comprising the steps of:
 - (a) reducing the disulfide bonds of a first sample from a biological mixture containing proteins and peptides;
 - (b) labeling proteins and peptides in the first sample with a reagent which comprises a thiol-specific reactive group attached to a guanidino group via a linker which can be differentially labeled;
 - (c) separating the proteins and peptides from the sample;
 - (d) digesting the proteins to provide a mixture containing digestion peptides and peptides from the first sample; and
 - (e) subjecting the peptides of (d) to quantitative MS analysis and protein identification.
2. The method according to claim 1, wherein the peptides of (d) are subjected to matrix-assisted laser desorption/ionization (MALDI) - MS.
3. The method according to claim 1, wherein the reagent comprises a thiol-specific reactive group is selected from the group consisting of α -haloacetyl ($-X-CH_2CO-$, X = I, Br, or Cl) or a maleimide group having a structure selected from the group consisting of:






and




4. The method according to claim 1, wherein the linker comprises an alkyl chain having three to eight carbon atoms, optionally substituted with one or more amido groups, carboxy groups, or amino groups.
5. The method according to claim 1, wherein the proteins and peptides are further subjected to peptide mass mapping, said method further comprising the steps of:
- labeling proteins and peptides in a second sample with said reagent having heavy stable isotopes; and
 - mixing the first and second samples prior to the separation step, wherein the reagent in the labeling step contains light stable isotopes.
6. The method according to claim 1, wherein the linker in the reagent of step (b) contains a substitution of four to twelve atoms with a stable isotope.
7. The method according to claim 6, wherein the linker contains seven stable isotopes.
8. The method according to claim 6, wherein the hydrogen atoms are substituted with deuterium.
9. The method according to claim 5, wherein the reagent is selected from the group consisting of:





and



10. The method according to claim 5, wherein the separation step is performed using one dimensional or two dimensional polyacrylamide gel electrophoresis (1D or 2D-PAGE), or liquid chromatography.

11. The method according to claim 1, wherein the digestion step is performed in-gel or in solution.

12. A method for preparing peptides for MALDI-MS and subsequent data analysis, said method comprising the steps of:

(a) reducing the disulfide bonds of proteins from biological samples;

(b) labeling proteins in one sample with a reagent which comprises a thiol-specific reactive group attached to a guanidino group via a linker which is differentially labeled with light stable isotopes;

(c) labeling proteins in a second sample with a reagent having heavy stable isotopes;

(d) mixing the first and second labeled samples;

(e) separating the proteins from the mixture;

(f) digesting the proteins, thereby providing peptides ready for MALDI-MS analysis and protein identification.


13. The method according to claim 11, wherein the digestion step is performed using trypsin.

14. A compound useful in quantitative analysis of protein mixtures, said compound comprising a thiol-specific reactive group attached to a guanidino group via a linker which can be differentially labeled with stable isotopes.


15. The compound according to claim 14, wherein the linker contains four to twelve stable isotopes.

16. The compound according to claim 14, wherein the linker contains a substitution of at least six hydrogen atoms with deuterium.

17. The compound according to claim 14, selected from the group consisting of:



and



18. A reagent kit for the analysis of proteins by mass spectrometric analysis that comprises a compound of claim 14 or claim 17.

19. The reagent kit according to claim 18, comprising a set of substantially identical differentially labeled alkylating reagents.

20. The reagent kit according to claim 18, further comprising one or more proteolytic enzymes for use in digestion of proteins modified by said compounds.

SEQUENCE LISTING

<110> Genetics Institute, Inc.

<120> ISOTOPE-CODED IONIZATION-ENHANCING REAGENTS (ICIER) FOR
HIGH-THROUGHPUT PROTEIN IDENTIFICATION AND QUANTITATION USING
MATRIX-ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY

<130> GII5412-1APCT

<150> 60/242,645

<151> 2000-10-23

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 12

<212> PRT

<213> Peptide of CTLA4-IgG

<400> 1

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
1 5 10

<210> 2

<211> 12

<212> PRT

<213> Peptide of CTLA4-IgG

<400> 2

Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val
1 5 10

<210> 3

<211> 16

<212> PRT

<213> Peptide of CTLA4-IgG

<400> 3

Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala
1 5 10 15

<210> 4

<211> 21
 <212> PRT
 <213> Peptide of CTLA4-IgG

<400> 4

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
 1 5 10 15

Pro Glu Val Lys Phe
 20

<210> 5
 <211> 25
 <212> PRT
 <213> Peptide of CTLA4-IgG

<400> 5

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 1 5 10 15

Leu His Asn His Tyr Thr Gln Leu Ser
 20 25

<210> 6
 <211> 10
 <212> PRT
 <213> Peptide of Interleukin (IL)-12

<400> 6

Lys Thr Ser Ala Thr Val Ile Cys Arg Lys
 1 5 10

<210> 7
 <211> 14
 <212> PRT
 <213> Peptide of IL-12

<400> 7

Lys Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly
 1 5 10

<210> 8
<211> 16
<212> PRT
<213> Peptide of IL-12

<400> 8

Arg Tyr Tyr Ser Ser Ser Trp Ser Glu Trp Ala Ser Val Pro Cys Ser
1 5 10 15

<210> 9
<211> 21
<212> PRT
<213> Peptide of IL-12

<400> 9

Arg Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu
1 5 10 15

Ser Ala Glu Arg Val
20

<210> 10
<211> 20
<212> PRT
<213> Peptide of IL-12

<400> 10

Arg Phe Thr Cys Trp Trp Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe
1 5 10 15

Ser Val Lys Ser
20

<210> 11
<211> 16
<212> PRT
<213> Peptide of alpha-Lactoalbumin

<400> 11

Lys Ala Leu Cys Ser Glu Lys Leu Asp Gln Trp Leu Cys Glu Lys Leu
1 5 10 15

<210> 12
<211> 17
<212> PRT
<213> Peptide of alpha-Lactoalbumin

<400> 12

Lys Phe Leu Asp Asp Asp Leu Thr Asp Asp Ile Met Cys Val Lys Lys
1 5 10 15

Ile

<210> 13
<211> 23
<212> PRT
<213> Peptide of alpha-Lactoalbumin

<400> 13

Lys Ile Trp Cys Lys Asp Asp Gln Asn Pro His Ser Ser Asn Ile Cys
1 5 10 15

Asn Ile Ser Cys Lys Asp Phe
20

<210> 14
<211> 5
<212> PRT
<213> Peptide of Lysozyme

<400> 14

Arg Gly Cys Arg Leu
1 5

<210> 15
<211> 6
<212> PRT
<213> Peptide of Lysozyme

<400> 15

Arg Asn Arg Cys Lys Gly
1 5

<210> 16

<211> 11
<212> PRT
<213> Peptide of Lysozyme

<400> 16

Arg Cys Glu Leu Ala Ala Ala Met Lys Arg His
1 5 10

<210> 17
<211> 13
<212> PRT
<213> Peptide of Lysozyme

<400> 17

Arg Cys Lys Gly Thr Asp Val Gln Ala Trp Ile Arg Gly
1 5 10

<210> 18
<211> 14
<212> PRT
<213> Peptide of Lysozyme

<400> 18

Arg Trp Trp Cys Asn Asp Gly Arg Thr Pro Gly Ser Arg Asn
1 5 10

<210> 19
<211> 21
<212> PRT
<213> Peptide of Lysozyme

<400> 19

Arg His Gly Leu Asp Asn Tyr Arg Gly Tyr Ser Leu Gly Asn Trp Val
1 5 10 15

Cys Ala Ala Lys Phe
20

<210> 20
<211> 25
<212> PRT
<213> Peptide of Lysozyme

<400> 20

Arg Asn Leu Cys Asn Ile Pro Cys Ser Ala Leu Leu Ser Ser Asp Ile
1 5 10 15

Thr Ala Ser Val Asn Cys Ala Lys Lys
20 25

<210> 21

<211> 26

<212> PRT

<213> Peptide of Lysozyme

<400> 21

Arg Gly Tyr Ser Leu Gly Asn Trp Val Cys Ala Ala Lys Phe Glu Ser
1 5 10 15

Asn Phe Asn Thr Gln Ala Thr Asn Arg Asn
20 25

<210> 22

<211> 15

<212> PRT

<213> Peptide of Ribonuclease

<400> 22

Arg Glu Thr Gly Ser Ser Lys Tyr Pro Asn Cys Ala Tyr Lys Thr
1 5 10 15

<210> 23

<211> 24

<212> PRT

<213> Peptide of Ribonuclease

<400> 23

Arg Cys Lys Pro Val Asn Thr Phe Val His Glu Ser Leu Ala Asp Val
1 5 10 15

Gln Ala Val Cys Ser Gln Lys Asn
20

<210> 24

<211> 27

<212> PRT

<213> Peptide of Ribonuclease

<400> 24

Lys Thr Thr Gln Ala Asn Lys His Ile Ile Val Ala Cys Glu Gly Asn
 1 5 10 15

Pro Tyr Val Pro Val His Phe Asp Ala Ser Val
 20 25

<210> 25

<211> 11

<212> PRT

<213> Peptide of Trypsinogen

<400> 25

Lys Val Cys Asn Tyr Val Ser Trp Ile Lys Gln
 1 5 10

<210> 26

<211> 12

<212> PRT

<213> Peptide of Trypsinogen

<400> 26

Lys Ala Pro Ile Leu Ser Asp Ser Ser Cys Lys Ser
 1 5 10

<210> 27

<211> 15

<212> PRT

<213> Peptide of Trysinogen

<400> 27

Lys Cys Leu Lys Ala Pro Ile Leu Ser Asp Ser Ser Cys Lys Ser
 1 5 10 15

<210> 28

<211> 16

<212> PRT

<213> Peptide of Trypsinogen

<400> 28

Lys Leu Gln Gly Ile Val Ser Trp Gly Ser Gly Cys Ala Gln Lys Asn
 1 5 10 15

<210> 29
<211> 18
<212> PRT
<213> Peptide of Trypsinogen

<400> 29

Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Ser Gly
1 5 10 15

Lys Leu

<210> 30
<211> 23
<212> PRT
<213> Peptide of Trypsinogen

<400> 30

Lys Ser Ala Tyr Pro Gly Gln Ile Thr Ser Asn Met Phe Cys Ala Gly
1 5 10 15

Tyr Leu Glu Gly Gly Lys Asp
 20

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 2002/046770 A3

- (51) International Patent Classification⁷: G01N 33/68, 33/58, C07C 279/14, C07D 207/456
- (21) International Application Number: PCT/US2001/050744
- (22) International Filing Date: 22 October 2001 (22.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/242,645 23 October 2000 (23.10.2000) US
- (71) Applicant: GENETICS INSTITUTE, LLC [US/US]; 87 Cambridge Park Drive, Cambridge, MA 02140 (US).
- (72) Inventors: QIU, Yongchang; 10 Old Colony Lane #7, Arlington, MA 02476 (US). WANG, Jack, H.; 522 Lowell Street, Lexington, MA 02420 (US). HEWICK, Rodney, M.; 42 Commonwealth Avenue #4, Boston, MA 02116 (US).
- (74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report: 26 February 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ISOTOPE-CODED IONIZATION-ENHANCING REAGENTS (ICIER) FOR HIGH-THROUGHPUT PROTEIN IDENTIFICATION AND QUANTITATION USING MATRIX-ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY

(57) Abstract: Arginine-containing cysteine-modifying compounds useful for MALDI-MS analysis of proteins are provided. These compounds termed isotope-coded ionization enhancement reagents (ICIER) can provide ionization enhancement in MALDI-MS, relative quantitation, and additional database searching constraints at the same time without any extra sample manipulation. More specifically, ICIER increase the ionization efficiency of cysteine-containing peptides by attachment of a guanidino functional group. ICIER also increase the overall hydrophilicity of these peptides due the hydrophilic nature of ICIER and thus increase the percentage of recovery of these peptides during sample handling and processing such as in-gel digestion or liquid chromatography. Finally, a combination of both light and heavy ICIER provides an accurate way to obtain relative quantitation of proteins by MALDI-MIS and additional database searching constraints (number of cysteine residues in every single peptide peak) to increase the confidence of protein identification by peptide mass mapping.

WO 2002/046770 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/50744

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 G01N33/58 C07C279/14 C07D207/456

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MCKENDRICK J E ET AL: "Rapid mass spectrometric determination of preferred irreversible proteinase inhibitors in combinatorial libraries"</p> <p>INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 176, no. 1-2, 1 June 1998 (1998-06-01), pages 113-124, XP004128436</p> <p>ISSN: 1387-3806</p> <p>page 116, right-hand column</p> <p>---</p> <p>--/--</p>	14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

28 October 2003

Date of mailing of the international search report

20/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Vogt, T

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/50744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SECHI S & CHAIT BT: "Modification of Cysteine Residue by Alkylation. A Tool in Peptide Mapping and Protein Identification" ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, COLUMBUS, US, vol. 70, no. 24, 15 December 1998 (1998-12-15), pages 5150-5158, XP002192468 ISSN: 0003-2700 the whole document	1-20
Y	GYGI S P ET AL: "QUANTITATIVE ANALYSIS OF COMPLEX PROTEIN MIXTURES USING ISOTOPE-CODED AFFINITY TAGS" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 17, no. 10, October 1999 (1999-10), pages 994-999, XP001010578 ISSN: 1087-0156 the whole document	1-20
Y	KRAUSE E ET AL: "The dominance of arginine-containing peptides in MALDI-derived tryptic mass fingerprints of proteins." ANALYTICAL CHEMISTRY, UNITED STATES 1 OCT 1999, vol. 71, no. 19, 1 October 1999 (1999-10-01), pages 4160-4165, XP002259382 ISSN: 0003-2700 the whole document	1-20
P,X	BRANCIA FRANCESCO L ET AL: "Improved matrix-assisted laser desorption/ionization mass spectrometric analysis of tryptic hydrolysates of proteins following guanidination of lysine-containing peptides" RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 14, no. 21, 2000, pages 2070-2073, XP009018972 ISSN: 0951-4198 the whole document	1-20
E	WO 02 48717 A (GENETICS INST LLC) 20 June 2002 (2002-06-20) the whole document	1-20

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/50744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KRATZER R ET AL: "Suppression effects in enzymatic peptide ladder sequencing using ultraviolet - matrix assisted laser desorption/ionization - mass spectrometry."</p> <p>ELECTROPHORESIS. GERMANY AUG 1998, vol. 19, no. 11, August 1998 (1998-08), pages 1910-1919, XP009019035</p> <p>ISSN: 0173-0835</p> <p>Introduction, in particular p. 1911, 1. col. 1st paragraph</p> <p>the whole document -----</p>	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/50744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0248717 A	20-06-2002	AU 4338502 A	24-06-2002
		CA 2426731 A1	20-06-2002
		EP 1330654 A2	30-07-2003
		WO 0248717 A2	20-06-2002
		US 2002164809 A1	07-11-2002
<hr/>			